FR3068355B1 - Ligands macrocycliques renforces, leurs complexes ainsi que leurs utilisations - Google Patents

Ligands macrocycliques renforces, leurs complexes ainsi que leurs utilisations Download PDF

Info

Publication number
FR3068355B1
FR3068355B1 FR1755933A FR1755933A FR3068355B1 FR 3068355 B1 FR3068355 B1 FR 3068355B1 FR 1755933 A FR1755933 A FR 1755933A FR 1755933 A FR1755933 A FR 1755933A FR 3068355 B1 FR3068355 B1 FR 3068355B1
Authority
FR
France
Prior art keywords
complexes
macrocyclic ligands
reinforced
ligands
reinforced macrocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1755933A
Other languages
English (en)
Other versions
FR3068355A1 (fr
Inventor
Raphael Tripier
Olivier Rousseaux
Fur Mariane Le
Maryline Beyler
Olivier Fougere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Centre National de la Recherche Scientifique CNRS
Univerdite de Bretagne Occidentale
Original Assignee
Guerbet SA
Centre National de la Recherche Scientifique CNRS
Univerdite de Bretagne Occidentale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet SA, Centre National de la Recherche Scientifique CNRS, Univerdite de Bretagne Occidentale filed Critical Guerbet SA
Priority to FR1755933A priority Critical patent/FR3068355B1/fr
Priority to US16/626,645 priority patent/US11155553B2/en
Priority to PCT/EP2018/067482 priority patent/WO2019002505A1/fr
Priority to EP18733626.8A priority patent/EP3645534A1/fr
Publication of FR3068355A1 publication Critical patent/FR3068355A1/fr
Application granted granted Critical
Publication of FR3068355B1 publication Critical patent/FR3068355B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux ligands macrocycliques ainsi que leurs complexes, notamment radioactifs, leurs utilisations ainsi que leur procédé de préparation. Lesdits ligands présentant un noyau pyclène renforcé.
FR1755933A 2017-06-28 2017-06-28 Ligands macrocycliques renforces, leurs complexes ainsi que leurs utilisations Active FR3068355B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR1755933A FR3068355B1 (fr) 2017-06-28 2017-06-28 Ligands macrocycliques renforces, leurs complexes ainsi que leurs utilisations
US16/626,645 US11155553B2 (en) 2017-06-28 2018-06-28 Reinforced macrocyclic ligands, complexes thereof, and uses of same
PCT/EP2018/067482 WO2019002505A1 (fr) 2017-06-28 2018-06-28 Ligands macrocycliques renforcés, leurs complexes ainsi que leurs utilisations
EP18733626.8A EP3645534A1 (fr) 2017-06-28 2018-06-28 Ligands macrocycliques renforcés, leurs complexes ainsi que leurs utilisations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1755933A FR3068355B1 (fr) 2017-06-28 2017-06-28 Ligands macrocycliques renforces, leurs complexes ainsi que leurs utilisations
FR1755933 2017-06-28

Publications (2)

Publication Number Publication Date
FR3068355A1 FR3068355A1 (fr) 2019-01-04
FR3068355B1 true FR3068355B1 (fr) 2020-12-11

Family

ID=60138467

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1755933A Active FR3068355B1 (fr) 2017-06-28 2017-06-28 Ligands macrocycliques renforces, leurs complexes ainsi que leurs utilisations

Country Status (4)

Country Link
US (1) US11155553B2 (fr)
EP (1) EP3645534A1 (fr)
FR (1) FR3068355B1 (fr)
WO (1) WO2019002505A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4124361B1 (fr) * 2021-07-30 2024-01-31 Guerbet Ligands macrocycliques avec groupement(s) picolinate(s), leurs complexes ainsi que leurs utilisations medicales

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046172B1 (fr) 2015-12-24 2019-05-31 Guerbet Ligands macrocycliques avec groupement(s) picolinate(s), leurs complexes ainsi que leurs utilisations medicales
US20210017180A1 (en) * 2018-03-30 2021-01-21 Centre National De La Recherche Scientifique Pyclen-based macrocyclic ligands, chelates thereof and uses thereof

Also Published As

Publication number Publication date
EP3645534A1 (fr) 2020-05-06
FR3068355A1 (fr) 2019-01-04
WO2019002505A1 (fr) 2019-01-03
US20200157101A1 (en) 2020-05-21
US11155553B2 (en) 2021-10-26

Similar Documents

Publication Publication Date Title
MA43187B1 (fr) Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
EA201890079A1 (ru) Клеточная система для направленной доставки активного ингредиента
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EA202092987A3 (ru) Липид, содержащий докозапентаеновую кислоту
EA201792613A1 (ru) Модуляторы cot и способы их применения
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MX360499B (es) Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas.
BR112016015105A2 (pt) Conjugados var2csa-droga
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
EP3943188A3 (fr) Conception, synthèse et caractérisation de réseaux métallo-organiques
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
FR3046172B1 (fr) Ligands macrocycliques avec groupement(s) picolinate(s), leurs complexes ainsi que leurs utilisations medicales
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
MA42743A1 (fr) Molécules d'anticorps multispécifiques ayant une spécificité pour tnf-alpha, il-17a et il-17f
EA201391360A1 (ru) Профилактика или снижение накипи в производстве экстракционной фосфорной кислоты
MX2015011386A (es) Metodo para tratar cancer pancreatico.
BR112015026561A2 (pt) artigo compósito e método de fabricação de um artigo compósito
FR3068355B1 (fr) Ligands macrocycliques renforces, leurs complexes ainsi que leurs utilisations
MA39387A1 (fr) Colorants réactifs fluorescents, procédé de production et utilisation de ceux-ci
MX2023009431A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
FR3058143B1 (fr) Nanocorps anti-tau
MX2019014291A (es) Metodo de tratamiento.
EP3656780A3 (fr) Procédé
TR201716062A2 (tr) Bi̇r eksozomal terapöti̇k taşiyici üreti̇m yöntemi̇ ve bu yönteme uygun bi̇r şeki̇lde elde edi̇len bi̇r eksozomal terapöti̇k taşiyici
EA201201647A1 (ru) Способ получения f-18 меченных лигандов бета-амилоида

Legal Events

Date Code Title Description
PLSC Publication of the preliminary search report

Effective date: 20190104

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7